Literature DB >> 20889950

Secondary chondrosarcoma.

Patrick P Lin1, Charbel D Moussallem, Michael T Deavers.   

Abstract

Secondary chondrosarcoma is a distinctive type of tumor that originates from a preexisting cartilaginous lesion. Most commonly, it is associated with solitary or multiple osteochondromas. A fraction of cases arises from other conditions, such as Maffucci syndrome and Ollier disease. A sudden increase in the size of the cartilaginous cap of an osteochondroma is a sign of malignant transformation to secondary chondrosarcoma. However, there is no strict cutoff in terms of thickness of the cartilaginous cap that can be regarded as being pathognomonic of malignancy. Most cases of secondary chondrosarcoma are low to intermediate grade. Distant metastasis is uncommon, and the prognosis is good for most patients. Overall survival at 5 years is approximately 90%. Surgical resection with wide margins is the best treatment option, but local recurrence remains a significant problem in approximately 10% to 20% of patients. Patients with secondary chondrosarcoma of the pelvis are especially at risk for local recurrence.

Entities:  

Mesh:

Year:  2010        PMID: 20889950     DOI: 10.5435/00124635-201010000-00004

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  17 in total

1.  Secondary chondrosarcoma of the pelvis arising from a solitary exostosis in an 11-year-old patient: a case report with 5-year follow-up.

Authors:  Lukas M Nystrom; Barry R DeYoung; Jose A Morcuende
Journal:  Iowa Orthop J       Date:  2013

2.  Cell cycle deregulation and mosaic loss of Ext1 drive peripheral chondrosarcomagenesis in the mouse and reveal an intrinsic cilia deficiency.

Authors:  Carlos E de Andrea; Ju-Fen Zhu; Huifeng Jin; Judith V M G Bovée; Kevin B Jones
Journal:  J Pathol       Date:  2015-03-03       Impact factor: 7.996

Review 3.  A systematic review of selected musculoskeletal late effects in survivors of childhood cancer.

Authors:  Prasad L Gawade; Melissa M Hudson; Sue C Kaste; Joseph P Neglia; Karen Wasilewski-Masker; Louis S Constine; Leslie L Robison; Kirsten K Ness
Journal:  Curr Pediatr Rev       Date:  2014

Review 4.  Wnt/β-catenin pathway in bone cancers.

Authors:  Jian Tian; Hongbo He; Guanghua Lei
Journal:  Tumour Biol       Date:  2014-08-13

5.  Radiographic Enchondroma Surveillance: Assessing Clinical Outcomes and Costs Effectiveness.

Authors:  Craig C Akoh; Ethan Craig; Alexander M Troester; Benjamin J Miller
Journal:  Iowa Orthop J       Date:  2019

6.  Is bone scintigraphy necessary in the initial surgical staging of chondrosarcoma of bone?

Authors:  Hassan Douis; Steven L James; Robert J Grimer; Mark A Davies
Journal:  Skeletal Radiol       Date:  2011-09-03       Impact factor: 2.199

7.  Diagnosis and evolution of the benign tumor osteochondroma.

Authors:  Iulia Bailescu; Mihai Popescu; Lavinia Raluca Sarafoleanu; Simona Bondari; Corneliu Sabetay; Mihaela Roxana Mitroi; Mihaela-Jana Tuculina; Dana-Maria Albulescu
Journal:  Exp Ther Med       Date:  2021-12-01       Impact factor: 2.447

Review 8.  Osteochondromas: An Updated Review of Epidemiology, Pathogenesis, Clinical Presentation, Radiological Features and Treatment Options.

Authors:  Kostas Tepelenis; Georgios Papathanakos; Aikaterini Kitsouli; Theodoros Troupis; Alexandra Barbouti; Konstantinos Vlachos; Panagiotis Kanavaros; Panagiotis Kitsoulis
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

9.  Hemorrhagic chondrosarcoma in a patient with Ollier disease: Case report and literature review.

Authors:  Marion Alicia Hughes; William Delfyett; Paul Gardner; Leonidas Arvanitis; Tanya Rath
Journal:  Radiol Case Rep       Date:  2015-12-07

Review 10.  Chondrosarcoma-from Molecular Pathology to Novel Therapies.

Authors:  Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.